ATE23716T1 - 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. - Google Patents

5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Info

Publication number
ATE23716T1
ATE23716T1 AT83100449T AT83100449T ATE23716T1 AT E23716 T1 ATE23716 T1 AT E23716T1 AT 83100449 T AT83100449 T AT 83100449T AT 83100449 T AT83100449 T AT 83100449T AT E23716 T1 ATE23716 T1 AT E23716T1
Authority
AT
Austria
Prior art keywords
carbon atoms
hydrogen
trinor
prostaglandin
phenylene
Prior art date
Application number
AT83100449T
Other languages
English (en)
Inventor
Kiyotaka Ohno
Hiroshi Nagase
Kazuhisa Matsumoto
Shintaro Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11630492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE23716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE23716T1 publication Critical patent/ATE23716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/12—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids
    • C07C29/124—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids of halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/56—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by isomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT83100449T 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. ATE23716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57006150A JPS58124778A (ja) 1982-01-20 1982-01-20 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
EP83100449A EP0084856B2 (de) 1982-01-20 1983-01-19 5,6,7-Trinor-4,8-inter-m-phenylen-prostaglandin I2-Derivate

Publications (1)

Publication Number Publication Date
ATE23716T1 true ATE23716T1 (de) 1986-12-15

Family

ID=11630492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83100449T ATE23716T1 (de) 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Country Status (8)

Country Link
US (1) US4474802A (de)
EP (1) EP0084856B2 (de)
JP (1) JPS58124778A (de)
AT (1) ATE23716T1 (de)
AU (1) AU556348B2 (de)
CA (1) CA1226280A (de)
DE (1) DE3367774D1 (de)
ZA (1) ZA83328B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232776B1 (de) * 1986-01-24 1990-10-24 Toray Industries, Inc. 2,5,6,7-Tetranor-4,8-inter-M-phenylen-PGI2-Derivate
US4880939A (en) * 1986-12-11 1989-11-14 Toray Industries 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives
EP0463162B1 (de) * 1989-02-27 1994-05-11 Toray Industries, Inc. VERFAHREN ZUR HERSTELLUNG VON 5,6,7, -TRINOR- 4,8,-INTER-m-PHENYLEN PGI,2 Abkömmlingen
DK0389162T3 (da) * 1989-03-14 1994-02-14 Toray Industries 2,5,6,7-Tetranor-4,8-inter-m-phenylen PGI2 derivater
JP2608135B2 (ja) * 1989-03-31 1997-05-07 科研製薬株式会社 糖尿病性神経障害治療剤
DE4104607A1 (de) * 1991-02-12 1992-08-13 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
JP3230246B2 (ja) * 1991-04-11 2001-11-19 東レ株式会社 悪性腫瘍転移抑制剤
US5233059A (en) * 1991-07-25 1993-08-03 Iowa State University Research Foundation, Inc. Synthesis of benzoprostacyclins using palladium catalysis
US5169959A (en) * 1991-09-23 1992-12-08 Iowa State University Research Foundation, Inc. Free radical-catalyzed synthesis of benzoprostacyclins
CA2099667C (en) * 1991-10-25 1999-04-13 Shinya Ueno Agent for treating hepatic diseases
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
ES2101333T3 (es) * 1992-08-07 1997-07-01 Schering Ag Utilizacion de derivados de prostano para la preparacion de un medicamento destinado al tratamiento de la poliartritis cronica.
DE4226615C1 (de) * 1992-08-07 1994-05-19 Schering Ag Verwendung von Prostan-Derivaten zur Behandlung von chronischer Polyarthritis
EP0621273B1 (de) * 1992-09-18 1998-12-09 Toray Industries, Inc. Sulfonsäure derivat und deren pharmazeutische verwendung
JPH07126161A (ja) * 1993-10-29 1995-05-16 Toray Ind Inc 心不全治療剤
JP3541417B2 (ja) * 1994-02-24 2004-07-14 日産化学工業株式会社 フェニル置換ヒドロキシシクロペンテノン類、ペンタノン類及びフェニル置換プロスタグランジンｉ２類中間体並びにその製造法及び光学分割法
PT742011E (pt) * 1994-11-17 2002-10-31 Toray Industries Preparacao que pode ser absorvida por via percutanea
CN1127336C (zh) * 1995-02-27 2003-11-12 东丽株式会社 肺性心病治疗剂
CZ168896A3 (en) * 1995-06-27 1997-01-15 Egyt Gyogyszervegyeszeti Gyar Oxaindene derivatives and process for preparing thereof
DE19530884C2 (de) * 1995-08-11 1997-07-31 Schering Ag Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
KR19990028646A (ko) 1996-05-07 1999-04-15 마에다 가쯔노스께 안과용제
US6201015B1 (en) * 1996-09-17 2001-03-13 Toray Industries, Inc. Therapeutic method for thrombocytopathy treatment
KR20000065039A (ko) * 1997-02-27 2000-11-06 히라이 가쯔히꼬 폐순환 개선제
WO1998040073A1 (fr) * 1997-03-13 1998-09-17 Toray Industries, Inc. Medicament pour traiter les lesions vasculaires diabetiques
ES2328191T3 (es) * 1997-03-14 2009-11-10 Toray Industries, Inc. Preparacion de derivado de la prostaglandina i de liberacion sostenida.
US6653345B2 (en) 1997-09-16 2003-11-25 Toray Industries, Inc. C-C chemokine synthesis inhibitor
KR20010033562A (ko) 1997-12-26 2001-04-25 오노다 마사요시 서방성 의약 조성물
JP4019481B2 (ja) 1998-01-23 2007-12-12 ソニー株式会社 情報処理装置および方法、情報処理システム、並びに提供媒体
WO2000009161A1 (fr) * 1998-08-12 2000-02-24 Toray Industries, Inc. Agents qui regulent la production de l'inhibiteur 1 des activateurs du plasminogene
WO2000009135A1 (en) * 1998-08-14 2000-02-24 Toray Industries, Inc. Peridermal cell protecting agents
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
HU227157B1 (en) * 2001-07-30 2010-09-28 Chinoin Gyogyszer Es Vegyeszet Production of beraprost ester by selective oxidation
JP3340732B1 (ja) * 2001-10-05 2002-11-05 日本医薬品工業株式会社 シクロペンタベンゾフラン誘導体の製造方法及びその製造原料となる新規化合物
GB0215757D0 (en) * 2002-07-08 2002-08-14 Cascade Biochem Ltd Benzoprostacyclin intermediates methods for their preparation and products derived therefrom
CN101439039B (zh) 2003-05-09 2012-06-13 东丽株式会社 增强剂
WO2005000316A1 (ja) * 2003-06-25 2005-01-06 Cardiovascular Institute, Ltd. 性交機能改善用外用製剤
ES2451627T3 (es) 2005-07-08 2014-03-28 Toray Industries, Inc. Agente terapéutico y método de tratamiento para mejorar uremia
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
SMT201700592T1 (it) 2008-08-13 2018-03-08 Actelion Pharmaceuticals Ltd Composizioni terapeutiche contenenti macitentan
CN102655859A (zh) 2009-10-14 2012-09-05 格穆斯药业股份有限公司 病毒感染的组合疗法治疗
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
EP3461817B1 (de) 2011-06-16 2020-11-04 Lung Biotechnology Inc. Kaliumsalz von beraprost
CN103509044A (zh) * 2012-06-21 2014-01-15 上海天伟生物制药有限公司 贝前列素钠中间体及其制备方法
DK3175852T3 (da) * 2012-07-19 2019-05-27 Cayman Chemical Co Inc Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
CN103242274B (zh) * 2013-05-22 2014-11-05 孙威 一种贝前列素钠化合物及其制备方法
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3334714A1 (de) 2015-08-12 2018-06-20 United Therapeutics Corporation Verfahren zur herstellung von beraprost
CN106632372B (zh) * 2016-09-26 2019-04-02 上海北卡医药技术有限公司 一种中间体及其制备方法和用途
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
WO2019023605A1 (en) 2017-07-27 2019-01-31 Allergan, Inc. PROSTACYCLINE RECEPTOR AGONISTS FOR BODY GREASE REDUCTION
CN109305986B (zh) * 2018-11-13 2021-02-19 济南康和医药科技有限公司 一种贝前列素钠中间体的合成方法
US10577340B1 (en) * 2018-11-26 2020-03-03 Chirogate International Inc. Beraprost-314d crystals and methods for preparation thereof
EP3972599B1 (de) 2019-05-21 2025-10-22 Ardelyx, Inc. Kombination zur senkung des serum-phosphatspiegels bei einem patienten
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
CN112569181B (zh) * 2019-09-27 2023-03-21 中国科学院上海高等研究院 一种快速增溶肾上腺素的方法
EP4103192A4 (de) 2020-02-12 2024-02-21 Cytoagents, Inc. Zusammensetzungen und verfahren zur behandlung von coronavirusinfektionen
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法
WO2023276983A1 (ja) * 2021-06-28 2023-01-05 大内新興化学工業株式会社 ベラプロストまたは光学活性体の合成中間体およびその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
JPS5931510B2 (ja) * 1979-09-03 1984-08-02 東レ株式会社 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPS57144276A (en) * 1981-03-03 1982-09-06 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative

Also Published As

Publication number Publication date
CA1226280A (en) 1987-09-01
EP0084856B2 (de) 1994-05-04
US4474802A (en) 1984-10-02
EP0084856A1 (de) 1983-08-03
AU1060983A (en) 1983-07-28
JPS58124778A (ja) 1983-07-25
ZA83328B (en) 1983-10-26
EP0084856B1 (de) 1986-11-20
AU556348B2 (en) 1986-10-30
DE3367774D1 (de) 1987-01-08
JPH0153672B2 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
ATE23716T1 (de) 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.
ES527954A1 (es) Un procedimiento para preparar isoxazoles
IL56288A (en) 15-deoxy-16-hydroxy-2-decarboxy-2-hydroxymethylprostaglandin derivatives and their preparation
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
ES8401961A1 (es) Procedimiento para la preparacion de nuevas n-(4-indolil-piperidino-alcohil-bencimidazolonas sustituidas.
ES8304567A1 (es) "un procedimiento para preparar nuevos derivados de la n-dihidrotiazolil-3-quinolein-carboxamida".
ES8800145A1 (es) Un procedimiento para preparar un derivado de semicarbazida
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
MX9206127A (es) Compuestos de acetileno
JPS5750989A (en) Imidazole compound
IL77124A (en) 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-one compoundds,their preparation and pharmaceutical compositions containing them
AU550340B2 (en) Dibenzazepine derivatives
DE3266845D1 (en) Hydrocortisone derivatives, their preparation and their utilization
AU562253B2 (en) Thiazolothienoazepine or pyridiue derivatives
ES8305758A1 (es) "un procedimiento para la preparacion de 2-(1,4-benzodioxan-2-il-metil)-imidazolina".
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
ES8401008A1 (es) Procedimiento para la preparacion de derivados de carbaciclina.
DE3264556D1 (en) Sulfimines, their salts and their preparation, and pharmaceutical compositions containing them
JPS52100470A (en) Synthesis of hydantoin derivatives
DE3363575D1 (en) Furyloxazolylacetic acid derivatives, process for preparing same and pharmaceutical compositions containing same
ES8103742A2 (es) Un procedimiento de preparacion de nuevos derivados de 1,3-benzodioxina
ES459705A1 (es) Procedimiento para la preparacion de derivados de hidracina-piridacina.
IL70103A0 (en) Semicarbazides,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time